UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJF)’s share price gapped down before the market opened on Monday . The stock had previously closed at $321.05, but opened at $294.00. UCB shares last traded at $310.14, with a volume of 8 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on UCBJF shares. The Goldman Sachs Group reissued a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research initiated coverage on shares of UCB in a research report on Monday, February 23rd. They issued an “outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy”.

UCB Trading Down 3.4%

The company’s 50 day simple moving average is $295.42 and its 200-day simple moving average is $299.17. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.